.png)
.png)
Executive Vice President
Institute for Clinical Pharmacodynamics
Disclosure(s): Adagio Therapeutics, Inc: Grant/Research Support, Grant/Research Support, Grant/Research Support; Amplyx Pharmaceuticals, Inc: Grant/Research Support, Grant/Research Support, Grant/Research Support; AN2 Therapeutics: Grant/Research Support, Grant/Research Support, Grant/Research Support; Antabio SAS: Grant/Research Support, Grant/Research Support, Grant/Research Support; Arcutis Biotherapeutics, Inc: Grant/Research Support, Grant/Research Support, Grant/Research Support; B. Braun Medical Inc: Grant/Research Support, Grant/Research Support, Grant/Research Support; Basilea Pharmaceutica: Grant/Research Support, Grant/Research Support, Grant/Research Support; Boston Pharmaceuticals: Grant/Research Support, Grant/Research Support, Grant/Research Support; Bravos Biosciences: Ownership Interest, Ownership Interest, Ownership Interest; Celdara Medical LLC: Grant/Research Support, Grant/Research Support, Grant/Research Support; Cidara Therapeutics Inc: Grant/Research Support, Grant/Research Support, Grant/Research Support; Cipla USA: Grant/Research Support, Grant/Research Support, Grant/Research Support; Crestone Inc.: Grant/Research Support, Grant/Research Support, Grant/Research Support; CXC: Grant/Research Support, Grant/Research Support, Grant/Research Support; Debiopharm International SA: Grant/Research Support, Grant/Research Support, Grant/Research Support; Entasis Therapeutics: Grant/Research Support, Grant/Research Support, Grant/Research Support; Evopoint Biosciences Co.: Grant/Research Support, Grant/Research Support, Grant/Research Support; Fedora Pharmaceuticals: Grant/Research Support, Grant/Research Support, Grant/Research Support; GlaxoSmithKline: Grant/Research Support, Grant/Research Support, Grant/Research Support; Hoffmann-La Roche: Grant/Research Support, Grant/Research Support, Grant/Research Support; ICPD: Ownership Interest, Ownership Interest, Ownership Interest; ICPD Biosciences, LLC.: Ownership Interest, Ownership Interest, Ownership Interest; Insmed Inc: Grant/Research Support, Grant/Research Support, Grant/Research Support; Iterum Therapeutics Limited: Grant/Research Support, Grant/Research Support, Grant/Research Support; Kaizen Bioscience, Co.: Grant/Research Support, Grant/Research Support, Grant/Research Support; KBP Biosciences USA: Grant/Research Support, Grant/Research Support, Grant/Research Support; Lassen Therapeutics: Grant/Research Support, Grant/Research Support, Grant/Research Support; Matinas Biopharma: Grant/Research Support, Grant/Research Support, Grant/Research Support; Meiji Seika Pharma Co., Ltd.: Grant/Research Support, Grant/Research Support, Grant/Research Support; Melinta Therapeutics: Grant/Research Support, Grant/Research Support, Grant/Research Support; Menarini Ricerche S.p.A: Grant/Research Support, Grant/Research Support, Grant/Research Support; Mutabilis: Grant/Research Support, Grant/Research Support, Grant/Research Support; Nabriva Therapeutics AG: Grant/Research Support, Grant/Research Support, Grant/Research Support; Novartis Pharmaceuticals Corp: Grant/Research Support, Grant/Research Support, Grant/Research Support; Paratek Pharmaceuticals, Inc.: Grant/Research Support, Grant/Research Support, Grant/Research Support; PureTech Health: Grant/Research Support, Grant/Research Support, Grant/Research Support; Sfunga Therapeutics: Grant/Research Support, Grant/Research Support, Grant/Research Support; Spero Therapeutics: Grant/Research Support, Grant/Research Support, Grant/Research Support; Suzhou Sinovent Pharmaceuticals Co.: Grant/Research Support, Grant/Research Support, Grant/Research Support; TauRx Therapeutics: Grant/Research Support, Grant/Research Support, Grant/Research Support; Tetraphase Pharmaceuticals: Grant/Research Support, Grant/Research Support, Grant/Research Support; tranScrip Partners: Grant/Research Support, Grant/Research Support, Grant/Research Support; Utility Therapeutics: Grant/Research Support, Grant/Research Support, Grant/Research Support; Valanbio Therapeutics, Inc: Grant/Research Support, Grant/Research Support, Grant/Research Support; VenatoRx: Grant/Research Support, Grant/Research Support, Grant/Research Support; Wockhardt Bio AG: Grant/Research Support, Grant/Research Support, Grant/Research Support
Dr. Bhavnani is the Executive Vice President, Translational Medicine at the Institute for Clinical Pharmacodynamics in Schenectady, New York. Her areas of scientific inquiry primarily involve anti-infective translational science and antimicrobial resistance. Her interest in anti-infective translational science involves the integration of pre-clinical pharmacokinetic-pharmacodynamic data and early clinical pharmacokinetic data to identify dosage regimens that optimize the probability of positive clinical outcomes and minimize the potential of drug toxicities. Results based on these analyses have been presented to regulatory bodies to justify dose selection for clinical trials. Dr. Bhavnani has evaluated exposure-response relationships for antimicrobial agents using pre-clinical and clinical data, the results of which have been used to support decisions for dose selection and interpretive criteria for the in vitro susceptibility testing for numerous new drug applications. Dr. Bhavnani has also undertaken such analyses to support the reappraisal of interpretive criteria for in vitro susceptibility testing of existing antimicrobial agents.
Dr. Bhavnani holds many professional society memberships, including the American Society for Microbiology, the Infectious Disease Society of America, and the International Society of Anti-Infective Pharmacology. She is the author or co-author of over 250 peer-reviewed scientific publications, book chapters, or scientific abstracts and an Associate Editor for Diagnostic Microbiology and Infectious Disease. Dr. Bhavnani serves as a voting member to the United States Antimicrobial Susceptibility Test Committee. She has served on the IDWeek Program Planning Committee from 2012 to 2015 and the American Society for Microbiology-European Society of Clinical Microbiology and Infectious Diseases Program Planning Committee from 2017 to 2021.